Biological Studies of Attention-Deficit Disorder

  • Ronit Weizman
  • Abraham Weizman
  • Stephen I. Deutsch


The hypothesis of dopamine deficiency in the pathophysiology of attention-deficit disorder (ADD) was derived from epidemiologic and pharmacologic studies. The first evidence rises from the analogy between the symptoms of children suffering from attention-deficit disorder with hyperactivity (ADDH) and from children who suffered from the pandemic of von Economo’s encephalitis in the beginning of this century. As a result of the viral infection, children exhibited attentional and motor symptoms, while adults developed Parkinson’s disease. 1 Since Parkinson’s disease is related to dopamine deficiency it suggests2 that the behavioral disorder observed in ADDH children might also result from a dysfunction of the dopaminergic system. The therapeutic efficacy of stimulants supported the possibility that monoaminergic deficiency may play a role in this disorder.


Inverse Agonist Attention Deficit Disorder Hyperactive Child Dopamine Deficiency Bioi Psychiatry 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Raskin LA, Shaywitz SE, Shaywitz BA, et al : Neurochemical correlates of attention deficit disorder. Pediatr Clin North Am 31:385–395, 1984Google Scholar
  2. 2.
    Wender PH : Some speculations concerning a possible biochemical basis of minimal brain dysfunction. Life Sci 14:1605–1621, 1974PubMedCrossRefGoogle Scholar
  3. 3.
    Shetty T, Chase TN : Central monoamines and hyperkinesis of childhood. Neurology (NY) 26:1000–1006, 1976Google Scholar
  4. 4.
    Shaywitz BA, Cohen DJ, Bowers MB Jr : CSF monoamine metabolites in children with minimal brain dysfunction: Evidence for alteration of brain dopamine. A preliminary report. J Pediatr 90:67–71, 1977PubMedCrossRefGoogle Scholar
  5. 5.
    Arnold L, Wender P, McColskey K, et al : Levoamphetamine and dextroamphetamine: Comparative efficacy in the hyperkinetic syndrome: Assessment by target symptoms. Arch Gen Psychiatry 27:816–822, 1972PubMedCrossRefGoogle Scholar
  6. 6.
    Gittleman R, Klein D, Katz S, et al : Comparative effects of methylphenidate and thioridazine in hyperkinetic children. Arch Gen Psychiatry 33:1217–1231, 1976CrossRefGoogle Scholar
  7. 7.
    Weizman A, Weitz R, Szekely GW, et al : Combination of neuroleptic and stimulant treatment in attention deficit disorder with hyperactivity. J Am Acad Child Psychiatry 23:295–298, 1984PubMedCrossRefGoogle Scholar
  8. 8.
    Shaywitz BA, Klopper JH, Yager RD, et al : Paradoxical response to amphetamine in developing rats treated with 6-hydroxydopamine. Nature (Lond) 261:153–155, 1976CrossRefGoogle Scholar
  9. 9.
    Shaywitz BA, Yager RD, Klopper JH : Selective brain dopamine depletion in developing rats. An experimental model of minimal brain dysfunction. Science 191:305–308, 1976PubMedCrossRefGoogle Scholar
  10. 10.
    Rapoport JL, Buchsbaum M, Zahn T, et al : Dextroamphetamine: Cognitive and behavioral effects in normal prepubertal boys. Science 199:511–514, 1978CrossRefGoogle Scholar
  11. 11.
    Gittelman-Klein R, Klein DF : Methylphenidate effects in learning disabilities. I. Psychometric changes. Arch Gen Psychiatry 33:655–664, 1978CrossRefGoogle Scholar
  12. 12.
    Zametkin AJ, Rapoport JL: Neurobiology of attention deficit disorder with hyperactivity: Where have we come in 50 years? J Am Acad Child Adol Psychiatry 26:676–686, 1987CrossRefGoogle Scholar
  13. 13.
    Shekim WO, Dekirmenjian H, Chapel JI : Urinary catecholamine metabolites in hyperkinetic boys treated with d-amphetamine. Am J Psychiatry 134:1276–1279, 1977PubMedGoogle Scholar
  14. 14.
    Shekim WO, Dekirmenjian H, Chapel JL : Urinary MHPG excretion on minimal brain dysfunction and its modification by d-amphetamine. Am J Psychiatry 136:667–671, 1979PubMedGoogle Scholar
  15. 15.
    Shekim WO, Davis LG, Bylund DB, et al : Platelet MAO, in children with attention deficit disorder and hyperactivity. A pilot study. Am J Psychiatry 139:936–938, 1982PubMedGoogle Scholar
  16. 16.
    Yu-cun A, Yu-Feng W : Urinary 3-methoxy-4-hydroxyphenylglycol sulfate excretion in seventy-three school children with minimal brain dysfunction syndrome. Biol Psychiatry 19:861–870, 1984Google Scholar
  17. 17.
    Rapoport JL, Mikkelsen EJ, Ebert MH, et al : Urinary catecholamine and amphetamine excretion in hyperactive and normal boys. J Nerv Ment Dis 66:731–737, 1978Google Scholar
  18. 18.
    Khan AU, Dekirmenjian H : Urinary excretion of catecholamine metabolites in hyperkinetic child syndrome. Am J Psychiatry 138:108–112, 1981PubMedGoogle Scholar
  19. 19.
    Zametkin AJ, Rapoport JL : Noradrenergic hypothesis of attention deficit disorder with hyperactivity. A critical review, in Meltzer HY(ed), Psychopharmacology: The Third Generation of Progress. New York, Raven, 1987, pp 837–842Google Scholar
  20. 20.
    Zametkin AJ, Karoum FK, Linnoila M, et al : Stimulants, urinary catecholamines, and indoleamines in hyperactivity: A comparison of methylphenidate and dextroamphetamine. Arch Gen Psychiatry 42:251–255, 1985PubMedCrossRefGoogle Scholar
  21. 21.
    Mikkelsen E, Lake CR, Brown GL, et al : The hyperactive child syndrome. Peripheral sympathetic nervous system function and the effect of d-amphetamine. Psychiatr Res 4:157–169, 1981CrossRefGoogle Scholar
  22. 22.
    Kuczenski R : Stimulants, Neurochemical Behavioral and Clinical Perspectives. New York, Raven, 1983Google Scholar
  23. 23.
    Bunney BS, Walters JR, Kuhar MJ, et al : D & L amphetamine stereo-isomers: Comparative potencies in affecting the firing of central dopaminergic and noradrenergic neurons. Psychopharm Commun 1:177–190, 1975Google Scholar
  24. 24.
    Brown GL, Ebert MH, Hunt RD, et al : Urinary 3-methoxy-4-hydroxy-phenylglycol and homovanillic acid response to d-amphetamine in hyperactive children. Biol Psychiatry 16:779–778, 1981PubMedGoogle Scholar
  25. 25.
    Donnelly M, Zametkin AJ, Rapoport JL, et al : Treatment of hyperactivity with desipramine; plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels and clinical response. Clin Pharm Ther 39:72–81, 1986CrossRefGoogle Scholar
  26. 26.
    Zametkin AJ, Linnoila M, Karoum F, et al : Pemoline and urinary excretion of catecholamines and indolamines in children with attention deficit disorder. Am J Psychiatry 143:359–362, 1986PubMedGoogle Scholar
  27. 27.
    Shekim WO, Davis LG, Bylund DB, et al : Platelet MAO in children with attention deficit disorder and hyperactivity. A pilot study. Am J Psychiatry 139:936–938, 1982Google Scholar
  28. 28.
    Brown GL, Murphy DL, Langer DH, et al : Monoamine enzymes in hyperactivity: Response to damphetamine. Annual meeting. Am Acad Child Psychiatry, Toronto, 1984Google Scholar
  29. 29.
    Young JG, Cohen DJ, Waldo MC, et al : Platelet monoamine oxidase activity in children and adolescent with psychiatric disorder. Schizophr Bull 6:324–333, 1984Google Scholar
  30. 30.
    Zametkin AJ, Karoum F, Rapoport JL, et al : Treatment of hyperactive children with monoamine oxidase inhibitors. I. Clinical efficacy. Arch Gen Psychiatry 42:962–969, 1985Google Scholar
  31. 31.
    Hunt RD, Cohen DJ, Shaywitz SE, et al : Strategies for the neurochemistry of attention deficit disorder in children. Schizophr Bull 8:236–251, 1982PubMedGoogle Scholar
  32. 32.
    Hunt RB, Minderaa RB, Cohen DJ : Clonidine benefits children with attention deficit disorder and hyperactivity: Report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry 24:617–629, 1985PubMedCrossRefGoogle Scholar
  33. 33.
    Aghajanian GK, Bunney BS : Dopamine “autoreceptors”: Pharmacological characterization by microintophoretic single cell recording studies. Arch Pharmacol 297:1–7, 1977CrossRefGoogle Scholar
  34. 34.
    Lai S, Tolis G, Marin JB, et al : Effects of clonidine on growth hormone, prolactin luteinizing hormone and thyroid stimulating hormone levels in serum of normal men. J Clin Endocrinol Metab 41:703–708, 1975Google Scholar
  35. 35.
    Chamey DS, Heninger GR, Sternberg DE, et al : Adrenergic receptor sensitivity in depression: effects of clonidine in depressed patients and healthy subjects. Arch Gen Psychiatry 39:290–294, 1982CrossRefGoogle Scholar
  36. 36.
    Hunt RD, Cohen DJ, Anderson G, et al : Possible change in noradrenergic receptor sensitivity following methylphenidate treatment: Growth hormone and MHPG response to clonidine challenge in children in attention deficit disorder and hyperactivity. Life Sci 35:885–897, 1984PubMedCrossRefGoogle Scholar
  37. 37.
    McElroy J, DuPont A, Feldman R : The effect of fenfluramine and fluoxetine on the acquisition of a conditional avoidance response on rats. Psychopharmacology 77:356–359, 1982PubMedCrossRefGoogle Scholar
  38. 38.
    Orgen SO : Central serotonin neurons in avoidance learning: Interactions with noradrenaline and dopamine neurons. Pharmacol Biochem Behav 23:107–123, 1985CrossRefGoogle Scholar
  39. 39.
    Coleman M : Serotonin concentrations in whole blood of hyperactive children. J Pediatr 78:985–990, 1971PubMedCrossRefGoogle Scholar
  40. 40.
    Bhagavan HN, Coleman M, Coursin DB : The effect of pyridoxine hydrochloride on blood serotonin and pyridoxal phosphate contents in hyperactive children. Pediatrics 55:437–441, 1975PubMedGoogle Scholar
  41. 41.
    Ferguson HB, Pappas BA, Trites RL, et al : Plasma free and total tryptophan, blood serotonin, and the hyperactivity syndrome: No evidence for the serotonin deficiency hypothesis. Biol Psychiatry 16:231–238, 1981PubMedGoogle Scholar
  42. 42.
    Haslam RHA, Dalby JT : Blood serotonin levels in the attention deficit disorder. N Engl J Med 309:1328, 1983PubMedGoogle Scholar
  43. 43.
    Coleman M, Steinberg G, Tippett J, et al : A preliminary study of the effect of pyridoxine administration in a subgroup of hyperkinetic children: A double-blind crossover. Biol Psychiatry 14:741–751, 1979PubMedGoogle Scholar
  44. 44.
    Nemzer ED, Arnold LA, Votolato NA, et al : Amino acid supplementation as therapy for attention deficit disorder. J Am Acad Child Psychiatry 25:509–513, 1986PubMedCrossRefGoogle Scholar
  45. 45.
    Ritvo ER, Freeman BJ, Yuwiler A, et al : Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at 9 medical centers. Psychopharmacol Bull 22:133–140, 1986PubMedGoogle Scholar
  46. 46.
    Rapoport JUL, Zametkin A, Donnelly M, et al : New drug trials in attention deficit disorder. Psychopharmacol Bull 21:232–236, 1985PubMedGoogle Scholar
  47. 47.
    Donnelly M, Rapoport JL, Ismond DR : Fenfluramine treatment of childhood attention deficit disorder with hyperactivity: A preliminary report. Psychopharmacol Bull 22:152–154, 1986PubMedGoogle Scholar
  48. 48.
    Garfinfl B, Wender P, Solman L, et al : Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. J Am Acad Child Psychiatry 22:343–348, 1983CrossRefGoogle Scholar
  49. 49.
    Shell-Kruger K, Hasselager E : Studies on various amphetamine and clonidine on body temperature and brain 5-hydroxytryptamine metabolism in rats. Psychopharmacologia 36:189, 1974CrossRefGoogle Scholar
  50. 50.
    Sloviter RS, Drust EG, Connor JD : Evidence that serotonin mediates some behavioral effects of amphetamine. J Pharmacol Exp Ther 206:348–352, 1978PubMedGoogle Scholar
  51. 51.
    Heffner TG, Seiden LS : Possible involvement of serotonergic neurons in the reduction of locomotor hyperactivity caused by amphetamine in neonatal rated depleted of brain dopamine. Brain Res 244:81–90, 1982PubMedCrossRefGoogle Scholar
  52. 52.
    Lucot JB, Seiden LS : Effects of serotonergic agonists and antagonists on the locomotor activity of neonatal rats. Pharmacol Biochem Behav 24:537–541, 1986PubMedCrossRefGoogle Scholar
  53. 53.
    Concannon JT: Serotonin “agonists” in an animal model of attentional deficit disorder (ADD). Soc Neurosci Abs 12(pt 2): 1363 (abst 371.18)Google Scholar
  54. 54.
    Wender PH, Epstein RS, Kopin IJ, et al : Urinary monoamine metabolites in children with minimal brain dysfunction. Am J Psychiatry 127:1411–1415, 1971PubMedGoogle Scholar
  55. 55.
    Weizman A, Bemhout E, Weitz R, et al : Imipramine binding to platelets of children with attention deficit disorder with hyperactivity. Biol Psychiatry 23:491–496, 1988PubMedCrossRefGoogle Scholar
  56. 56.
    Rapoport J, Quinn P, Scirbanu N, et al : Platelet serotonin of hyperactive school boys. Br J Psychiatry 125:138–140, 1974PubMedCrossRefGoogle Scholar
  57. 57.
    Duka T, Stephens DN, Krause W, et al : Human studies on the benzodiazepine receptor antagonist pcarboline ZK 93426: Preliminary observations on psychotropic activity. Psychopharmacology 93:421–427, 1987PubMedCrossRefGoogle Scholar
  58. 58.
    Venault P, Chapouthier G, de Carvalho LP, et al : Benzodiazepine impairs and p-carboline enhances performance in learning and memory tasks. Nature (Lond) 321:864–866, 1986CrossRefGoogle Scholar
  59. 59.
    Amsten AFT, Segal DS, Neville HJ, et al : Naloxone augments electrophysiological signs of selective attention in man. Nature (Lond) 304:725–727, 1983CrossRefGoogle Scholar
  60. 60.
    Aigner TG, Mishkin M : Improved recognition memory in monkeys following naloxone administration. Psychopharmacology 94:21–23, 1988PubMedCrossRefGoogle Scholar
  61. 61.
    Deutsch SI : Rationale for the administration of opiate antagonists in treating infantile autism. Am J Ment Defic 90:631–635, 1986PubMedGoogle Scholar
  62. 62.
    Freed WJ, Wyatt RJ : Impairment of instrumental learning in rats by glutamic acid diethyl ester. Pharm Biochem Behav 14:223–226, 1981CrossRefGoogle Scholar
  63. 63.
    Pico RM, Keller E, Cherkin A, et al : Brain glutamate inhibition and amnesia: Evidence provided by proline analog action. Dev Brain Res 9:227–230, 1983CrossRefGoogle Scholar
  64. 64.
    Sahai S, Buselmaier W, Brussmann A : 2-Amino-4-phosphonobutyric acid selectively blocks two-way avoidance learning in the mouse. Neurosci Lett 56:137–142, 1985PubMedCrossRefGoogle Scholar
  65. 65.
    Morris RGM, Anderson E, Lynch GS, et al : Selective impairment of learning and blockade of long-term potentiation by an W-methyl-D-aspartate receptor antagonist, AP5. Nature (Lond) 319:774–776, 1986CrossRefGoogle Scholar
  66. 66.
    Kano M, Kato M : Quisqualate receptors are specifically involved in cerebellar synaptic plasticity. Nature (Lond) 325:276–279, 1987CrossRefGoogle Scholar
  67. 67.
    Deutsch SI, Morihisa JM : Glutamatergic abnormalities in Alzheimer’s disease and rational for clinical trials with L-glutamate. Clin Neuropharmacol 11:18–35, 1988PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1990

Authors and Affiliations

  • Ronit Weizman
    • 1
    • 2
  • Abraham Weizman
    • 3
    • 4
  • Stephen I. Deutsch
    • 5
    • 6
  1. 1.Pediatric DepartmentHasharon HospitalPetah TiqvaIsrael
  2. 2.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
  3. 3.Geha Psychiatric HospitalBeilinson Medical CenterPetah TiqvaIsrael
  4. 4.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
  5. 5.Psychiatry ServiceVeterans Administration Medical CenterUSA
  6. 6.Department of PsychiatryGeorgetown University School of MedicineUSA

Personalised recommendations